Colorectal cancer - historical

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main colorectal cancer page for current regimens.

4 regimens on this page
4 variants on this page


Metastatic disease, first-line

Fluorouracil & Methotrexate (MF)

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Wils et al. 2003 1992-1994 Phase 3 (C) MF & PALA Did not meet endpoints of RR/PFS/OS

References

  1. Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; EORTC Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. link to original article PubMed

Fluorouracil & Mitomycin

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Price et al. 2004 1996-1998 Phase 3 (C) Fluorouracil & Mitomycin; chronomodulated Did not meet endpoints of FFS/OS

References

  1. Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. link to original article PubMed

Fluorouracil & Semustine

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Baker et al. 1976 1973-1974 Phase 3 (C) 5-FU Superior ORR
Engstrom et al. 1982 (ECOG E4275) NR Phase 3 (E-switch-ic) 1. 5-FU, Semustine, Vincristine
2. 5-FU, Dacarbazine, Semustine
3. 5-FU, Dacarbazine, Semustine, Vincristine
4. 5-FU & Hydrea
Did not meet endpoints of RR/OS

References

  1. Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK; Southwest Oncology Group. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):1-7. link to original article PubMed
  2. ECOG E4275: Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982 Apr 15;49(8):1555-60. link to original article PubMed

FOLFOX chronotherapy

FOLFOX: FOLinic acid, Fluorouracil, OXaliplatin

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Lévi et al. 1997 1991-1993 Phase 3 (E-switch-ic) FOLFOX; CI Superior TTF

Note: This schedule is "chronomodulated"; see paper for details.

Chemotherapy

21-day cycles

References

  1. Lévi F, Zidani R, Misset JL; International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997 Sep 6;350(9079):681-6. link to original article contains dosing details in manuscript PubMed